Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety; in a 26-week phase 2 trial in 706 adults with overweight or obesity, once-weekly doses reduced body weight by 6.0% to 10.8% against 3.0% on placebo, with more nausea.
fact added identity: CAS registry number 1415456-99-3. · 2026-09-27 12:04 · somebody
fact added summary: Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety; in a 26-week phase 2 trial · 2026-09-27 12:04 · somebody
fact added summary: In a 68-week phase 3a trial in 3,417 adults, cagrilintide combined with semaglutide reduced body weight by 20.4% against · 2026-09-27 12:04 · somebody
citation added pmid 34798060 cited as emerging: Once-weekly cagrilintide reduced body weight dose-dependently in a phase 2 trial · 2026-09-27 12:04 · somebody
citation added pmid 40544433 cited as established: Cagrilintide with semaglutide (CagriSema) reduced body weight by 20.4% at 68 weeks (phase 3a) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.